Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts

Vertex Pharmaceuticals (VRTX) closed at $508.75, up 2.06%, outperforming the S&P 500's 0.33% gain. However, the stock has declined 2.88% over the past month. The company is scheduled to report earnings on November 2, 2026, with projected EPS of $4.84 (up 0.83% YoY) and quarterly revenue of $3.4 billion (up 10.49% YoY). Despite positive revenue growth expectations, the stock holds a Zacks Rank of #3 (Hold) with a Forward P/E of 26.52, trading at a premium to its industry average.